期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

流感疫苗佐剂的研究进展 被引量：5

下载PDF
导出
摘要 佐剂作为免疫增强剂应用于流感疫苗,对于增强疫苗的免疫原性、提高疫苗的免疫效果有十分重要的意义。本文主要介绍了目前已应用的佐剂和正在研究的佐剂在流感疫苗中的使用情况。
作者 王海漩 李卫东 廖国阳
机构地区 中国医学科学院中国协和医科大学医学生物学研究所
出处 《中国生物制品学杂志》 CAS CSCD 2007年第3期224-226,共3页 Chinese Journal of Biologicals
基金 云南省自然科学基金面上项目(2004C0070M) 2003年度云南省科技厅创新人才引培项目(2003PY07)
关键词 流感疫苗 佐剂
分类号 R373.13 [医药卫生—病原生物学]
  • 相关文献

参考文献12

  • 1Eickhoff TC,Myers M.Workshop summary.Aluminum in vaccines.Vaccine,2002,20(Suppl 3):S1-S4.
  • 2Puig BJ,Diez DJ,Perez HS,et al.Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.Vaccine,2004,23(3):283-289.
  • 3Sesardic D,Dobbelaer R.European union regulatory developments for new vaccine adjuvants and delivery systems.Vaccine,2004,22(19):2452-2456.
  • 4Kenney RT,Rabinovich RN,Pichyangkul S,et al.2nd meeting on novel adjuvants currently in/close to human clinical testing.Vaccine,2002,20(17-18):2155-2163.
  • 5Pearse MJ,Drane D.ISCOMATRIXTM adjuvant:a potent inducer of humoral and cellular immune response.Vaccine,2004,22(19):2391-2395.
  • 6王斌,徐苗.ISCOMATRIX^(TM)佐剂:细胞和体液免疫应答的有效诱导剂[J].国外医学（预防．诊断．治疗用生物制品分册）,2005,28(5):204-207. 被引量：5
  • 7Scheerlinck JP,Gekas S,Yen HH,et al.Local immune responses following nasal delivery of an adjuvanted influenza vaccine.Vaccine,2006,24(18):3929-3936.
  • 8Cooper CL,Davis HL,Morris ML,et al.Safety and immunogenicity of CPG7909 injection as an adjuvant to Fluarix influenza vaccine.Vaccine,2004,22(23-24):3136-3143.
  • 9Fritz JH,Brunner S,Birnstiel ML,et al.The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a Th2-type immune response to co-injected antigens.Vaccine,2004,22(25-26):3274-3284.
  • 10Bracci L,Canini I,Puzelli S,et al.Type Ⅰ IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.Vaccine,2005,23(23):2994-3004.

二级参考文献9

  • 1McNeela EO, Connan D, Jabbal-Gill I, et al. Mucosally delivered vaccine against diphtheria; formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
  • 2Ilium L,Watts P,Fisher AN,et al. Novel chitosan based delivery systems fornasal administration of a LHRH-analogue. STP Pharma,2000, 10:89-94.
  • 3Illum L, Jabbal-Gill I,Hinchcliffe M,et al. Chitosan as a novel nsal delivery system for vaccines. Advanced Arug Delivery Reviews, 2001,51:81-96.
  • 4Roy K,Hai QM,Shau KH, et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Med, 1999,5:387-391.
  • 5Chen Z, Shin-tesu K, Yukari H, et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine,2000,18:3214-3222.
  • 6Bacon A, Makin J, Sizer PJ, et al. Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens. Infection and Immunity, 2000,68: 5764-5770.
  • 7Pearse MJ,Drane D. ISCOMATRIX^TM adjuvant:a potent inducer of humoral and cellular immune responses. Vaccine, 2004,22:2391-2395.
  • 8Coulter A, Harris R, Davis R, et al. Intranasal vaccination with ISCOMATRIX^TM adjuvanted influenza vaccine. Vaccine, 2003,21: 946-949.
  • 9Sjolander A, Drane D,Maraskovsky E,et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine,2001,19: 2661-2665.

共引文献14

同被引文献43

  • 1常海艳,陈建军,方芳,陈则.流感病毒灭活疫苗新型佐剂——壳聚糖增强免疫作用研究[J].中国生物制品学杂志,2004,17(6):383-384. 被引量：12
  • 2王斌,徐苗.ISCOMATRIX^(TM)佐剂:细胞和体液免疫应答的有效诱导剂[J].国外医学（预防．诊断．治疗用生物制品分册）,2005,28(5):204-207. 被引量：5
  • 3高德民,王凤山.胸腺肽α1的特征与功能综述[J].中国生化药物杂志,2007,28(2):136-139. 被引量：20
  • 4萨姆布鲁克J,拉塞尔D W,黄培堂,王嘉玺,朱厚础,等译.分子克隆实验指南[M]3版.北京:科学出版社,2002..
  • 5Scholtissek C ,Steeh j,Krauss S ,et al . Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses[J]. J Virol,2002,76(4) : 1781-1786.
  • 6Aucouturier J,Dupuis L,Ganne V. Adjuvants designed for veterinary and human vaccines[J]. Vaccine, 2001,19 (6) : 2666-2672.
  • 7Zoltan Vajo, Lajos Kosa,Ildiko Visontay,et al. Inactivated Whole Virus Influenza A (H5N1)Vaccine[J]. Emerging Infectious Diseases, 2007,13(5) : 807-808.
  • 8Dumortier j, Schonig K, Oherwinkler H, et al. Liver- specific expression of interferon gamma following adenoviral gene transfer controis hepatitis B virus replication in mice[J]. Gene Ther, 9.005,12 (8) :668-677.
  • 9lain S. Karl G N. Anthony C. Boosting immunity to influenza H5N 1 with MF59-adjuvanted H5N3 A/Duck/SINGAPORE/97 vaccine in a primed human population [J].Vaccine, 2003, 21 ( 15 ), 1687- 1693.
  • 10Iorio AM,Francisci D,Camilloni B,et al. Antibody responses and HIV- 1 viral load in HIV- 1- seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non- adjuvanted subunit vaccine during highly active antiretroviral therapy[J]. Vaccine,2003,21(25-26):3629-3637.

引证文献5

二级引证文献4

中国生物制品学杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部